PT  - JOURNAL ARTICLE
AU  - Lannou, Erwann Le
AU  - Post, Benjamin
AU  - Haar, Shlomi
AU  - Brett, Stephen J.
AU  - Kadirvelu, Balasundaram
AU  - Faisal, A. Aldo
TI  - Clustering of patient comorbidities within electronic medical records enables high-precision COVID-19 mortality prediction
AID  - 10.1101/2021.03.29.21254579
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.29.21254579
4099  - http://medrxiv.org/content/early/2021/03/31/2021.03.29.21254579.short
4100  - http://medrxiv.org/content/early/2021/03/31/2021.03.29.21254579.full
AB  - We present an explainable AI framework to predict mortality after a positive COVID-19 diagnosis based solely on data routinely collected in electronic healthcare records (EHRs) obtained prior to diagnosis. We grounded our analysis on the ½ Million people UK Biobank and linked NHS COVID-19 records. We developed a method to capture the complexities and large variety of clinical codes present in EHRs, and we show that these have a larger impact on risk than all other patient data but age. We use a form of clustering for natural language processing of the clinical codes, specifically, topic modelling by Latent Dirichlet Allocation (LDA), to generate a succinct digital fingerprint of a patient’s full secondary care clinical history, i.e. their comorbidities and past interventions. These digital comorbidity fingerprints offer immediately interpretable clinical descriptions that are meaningful, e.g. grouping cardiovascular disorders with common risk factors but also novel groupings that are not obvious. The comorbidity fingerprints differ in both their breadth and depth from existing observational disease associations in the COVID-19 literature. Taking this data-driven approach allows us to avoid human-induction bias and confirmation bias during selection of what are important potential predictors of COVID-19 mortality. Together with age, these digital fingerprints are the single most important factor in our predictor. This holds the potential for improving individual risk profiling for clinical decisions and the identification of groups for public health interventions such as vaccine programmes. Combining our digital precondition fingerprints with demographic characteristics allow us to match or exceed the performance of existing state-of-the-art COVID-19 mortality predictors (EHCF) which have been developed through expert consensus. Our precondition fingerprinting and entire mortality prediction analytics pipeline are designed so as to be rapidly redeployable, e.g. for COVID-19 variants or other pre-existing diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementInfrastructure support for this research was provided by the Imperial NIHR Biomedical Research Centre. AAF acknowledges his UKRI Turing AI Fellowship (EP/V025449/1). Benjamin Post holds a PhD Studentship from the UKRI Centre for Doctoral Training in AI for Healthcare. The funders had no role in the design of this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC), which covers the UK. It also sought the approval in England and Wales from the Patient Information Advisory Group (PIAG) for gaining access to information that would allow it to invite people to participate. PIAG has since been replaced by the National Information Governance Board for Health & Social Care (NIGB). Instead of requiring each applicant to obtain separate ethics approval, UK Biobank has sought generic Research Tissue Bank (RTB) approval, which should cover the large majority of research using the resource. This approach is recommended by the National Research Ethics Service and UK Biobank's governing Research Ethics Committee (REC), which approved the application in 2010.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available from central access-controlled repository, and sufficient details included to identify specific dataset. All bona fide researchers can apply to use the UK Biobank resource for health-related research that is in the public interest." This research has been conducted using the UK Biobank Resource under application number 21770. https://www.ukbiobank.ac.uk/